Climb Aboard BIOL NOW-A Beautiful Long Lasting Growth Story Is About To Unfold
BIOL should experience 30% year over year growth in revenue through 2013 and into 2014 with breakeven and a profitable status coming into view during the second half of fiscal year 2013. Now is the time to get ahead of the curve. Buy these shares before the greater investment community gets their hands on this stock, CEO Frederico Pignatelli and his fine team have BIOL posied for outstanding performance. I see this stock as a current very strong buy. As for myself, I'm into BIOL with a very meaniningful position on a long term basis, hodling period of 12 to 36 months, with a share price target of $10.00/share. The due diligence I've done on BIOL points to it as being one of the best stock picks in the small cap health care sector of the stock makret. I highly recommend that you do your own due diligence and I think you will agree with me that BIOL merits your very strong investment consideration.